Stockholm, August 10, 2022: Elypta, a Swedish diagnostics company aiming to commercialize the first metabolism-based liquid biopsy for early detection of any cancer, today announced the appointment of Dr. Volker Liebenberg as Chief Medical Officer.
“We are truly delighted to have Dr. Liebenberg join the team. He brings a wealth of experience in IVD development to Elypta and shares our belief in the potential for liquid biopsies to drive early detection of cancer,” says Karl Bergman, Elypta CEO.
“It feels great to join a high-performing team, that is pursuing an amazing diagnostic opportunity. GAG biomarkers hold promise to detect multiple cancers early, and I look forward to bringing in my experience to drive their adoption,” says Dr. Liebenberg.
Dr. Liebenberg joins Elypta from Illumina, where he acted as the head of the Medical Affairs team in Europe, the Middle East, and Africa (EMEA). At Elypta, Volker will oversee the clinical development of Elypta’s platform for earlier detection of multiple cancers. Volker is a physician with more than 20 years of academic and industry experience in the research and commercialization of biomarkers. Volker has previously worked with several other molecular diagnostic companies including QIAGEN GmbH, Thermo Fisher Scientific Inc., and Epigenomics AG, with medical responsibility across multiple indications in oncology, infectious diseases, and prenatal screening.
Karl Bergman, CEO, Phone: +46 73 262 53 33, Email: karl.bergman@elypta.com
Media Nordics, Ola Bjorkman, Phone: +46 (0) 70 245 74 97, Email: ola.bjorkman@letemknow.se
Media International, Richard Hayhurst, Phone: +44 (0) 7711 821527, Email: richard@rhapr.eu
Elypta is a Swedish cancer diagnostics company focused on reducing cancer mortality by enabling earlier detection and closer monitoring. The metabolism-based liquid biopsy platform measures a novel panel of glycosaminoglycan biomarkers (GAGome) and algorithms trained to detect cancer-specific signatures. Elypta is advancing abroad study program across different cancers with the leading indications being early detection of recurrence in renal cell carcinoma and multi-cancer screening. www.elypta.com
